What is the Neurocrine Biosciences Inc (NBIX) price today?

The price of Neurocrine Biosciences Inc (NBIX) today is $133.25. This value reflects the latest market rate available on Pluang. Check the asset page for additional details such as 24-hour change, market trends, and trading volume.

What are the trading hours of US Stocks?

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.

Do I get a dividend from investing in US Stocks?

Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.

What is the fee for each transaction?

Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.

Trade on Pluang

One platform for all markets

Download

Investment

Features

Fees Safety

Academy

Pluang+

Home/Explore/US Market Price/Stocks/NBIX

Buy & Sell Neurocrine Biosciences Inc (NBIX) – Neurocrine Biosciences Inc Price Today

Overview Financials Technicals Analysis Corp Action About

24H

YTD

Aura AI Summary

Neurocrine Biosciences (NBIX) trades at $133.25, up 3.77% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with 98.18% gross margins and 16.73% net income margins, supported by positive analyst sentiment with 86% buy ratings. Recent developments include the $2.9 billion acquisition of Soleno Therapeutics, expanding its rare disease portfolio.

NBIX presents a compelling growth story with consistent earnings outperformance and strategic expansion through acquisitions. Key risks include integration challenges from the Soleno deal and competitive pressures in neurology markets. With a consensus price target of $180 representing 35% upside, the stock offers attractive potential despite premium valuation multiples.

Read full analysis

Key Stats

Market Cap
$13.40B
Sector
Health
3M Drawdown
-12.82%
Enterprise Value
$12.34B
Dividend Yield
-

$133.25

52W Low: $100.68

21 Apr 2025

52W High: $155.63

10 Dec 2025

Neurocrine Biosciences Inc (NBIX) is currently valued at a market capitalization of $13.40B, with an enterprise value of $12.34B. Over the past 52 weeks, Neurocrine Biosciences Inc has traded between a low of $100.68 and a high of $155.63, highlighting its annual price range. Over the past three months, Neurocrine Biosciences Inc has recorded a drawdown of -12.82%, reflecting recent price volatility.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Technical Indicators

Overall Summary

Bearish (4)Neutral (6)Bullish (13)

News

Benzinga4 mon ago

Clinical Miss For Neurocrine's Cerebral Palsy Drug, But Analysts See Limited Damage

The Motley Fool5 mon ago

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?

Globe Newswire8 mon ago

Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025

The Motley Fool9 mon ago

Neurocrine (NBIX) Q2 Revenue Jumps 17%

Globe Newswire9 mon ago

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

People also bought

US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

Market Cap
$13.40B
Sector
Health
3M Drawdown
-12.82%
Enterprise Value
$12.34B
Dividend Yield
-

$133.25

52W Low: $100.68

21 Apr 2025

52W High: $155.63

10 Dec 2025

Let’s invest in this asset by signing up or download!

Buy & Sell Neurocrine Biosciences Inc (NBIX) – Neurocrine Biosciences Inc Price Today

Aura AI Summary

Key Stats

About Neurocrine Biosciences Inc

People also bought

Key Stats

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store